Side Effects of lansoprazole: A Synthesis of Findings from 26 Studies

  1. Home
  2. Side Effects of lansoprazole
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of lansoprazole: A Synthesis of Findings from 26 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of lansoprazole: A Synthesis of Findings from 26 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Lansoprazole is a widely prescribed medication used to reduce stomach acid. However, several studies have indicated that lansoprazole can lead to various side effects. Research in 2 found that long-term use of lansoprazole can increase the risk of conditions like pneumonia, Clostridium difficile infection, osteoporosis, fractures, thrombocytopenia, rhabdomyolysis, anemia, iron deficiency, hypomagnesemia, vitamin B12 deficiency, and nephritis. 19 shows that lansoprazole may inhibit contractions of the uterine muscles in pregnant women. 16 discovered that lansoprazole can worsen hematologic toxicity caused by pemetrexed. A case study in 5 reported an instance of bullous pemphigoid induced by lansoprazole. 24 indicates that lansoprazole can be effective in preventing gastrointestinal issues caused by non-steroidal anti-inflammatory drugs (NSAIDs).

Reasons for Side Effects

The exact reasons behind lansoprazole's side effects are still not fully understood. However, it is believed that lansoprazole alters the stomach's internal environment by suppressing acid production. This alteration could potentially encourage bacterial growth or interfere with nutrient absorption. Lansoprazole may also affect various signaling pathways within cells, leading to a range of side effects.

Common Side Effects

Pneumonia

Lansoprazole has been linked to an increased risk of pneumonia. 2 found that short-term use of PPIs resulted in a 27% to 39% increase in pneumonia risk.

Clostridium difficile Infection

Lansoprazole can increase the risk of Clostridium difficile infection. 2 reports that individuals using PPIs had a 2.15 times higher risk of developing Clostridium difficile infection.

Osteoporosis

Lansoprazole may increase the risk of osteoporosis. 2 found a higher risk of fractures in individuals using lansoprazole.

Thrombocytopenia

Lansoprazole has been associated with thrombocytopenia. 2 reports instances of thrombocytopenia in individuals using lansoprazole.

Rhabdomyolysis

Lansoprazole can contribute to rhabdomyolysis. 2 reports cases of rhabdomyolysis in individuals using lansoprazole.

Anemia

Lansoprazole may cause anemia. 2 reports cases of anemia, iron deficiency, and vitamin B12 deficiency in individuals using lansoprazole.

Hypomagnesemia

Lansoprazole has been linked to hypomagnesemia. 2 reports instances of hypomagnesemia in individuals using lansoprazole. 1 presents a case study where lansoprazole caused hypomagnesemia. 3 suggests that lansoprazole could potentially cause hypomagnesemia.

Nephritis

Lansoprazole may cause nephritis. 2 reports cases of nephritis in individuals using lansoprazole.

Inhibition of Uterine Muscle Contractions

Lansoprazole might inhibit uterine muscle contractions in pregnant women. 19 demonstrated that lansoprazole inhibited uterine muscle contractions in vitro in pregnant women.

Worsening of Hematologic Toxicity

Lansoprazole can worsen hematologic toxicity caused by pemetrexed. 16 showed that concurrent use of lansoprazole and pemetrexed increased the risk of hematologic toxicity.

Bullous Pemphigoid

Lansoprazole has been associated with bullous pemphigoid. 5 reports a case study where lansoprazole induced bullous pemphigoid.

Side Effects Management

Pneumonia

To minimize the risk of pneumonia, it is crucial to use lansoprazole for the shortest possible duration. If you experience symptoms of pneumonia, seek medical attention immediately.

Clostridium difficile Infection

Using lansoprazole for the shortest possible time can help reduce the risk of Clostridium difficile infection. Consult a doctor promptly if you experience diarrhea or any other symptoms.

Osteoporosis

Prior to starting lansoprazole, it is advisable to have a bone density test to assess the risk of osteoporosis. Maintain a healthy lifestyle by consuming sufficient calcium and vitamin D, and engage in regular exercise.

Thrombocytopenia

If you experience symptoms of thrombocytopenia, seek medical attention immediately. The doctor may order blood tests and initiate appropriate treatment.

Rhabdomyolysis

If you experience symptoms of rhabdomyolysis, consult a doctor immediately. They may order blood tests and provide necessary treatment.

Anemia

If you experience symptoms of anemia, consult a doctor immediately. They may order blood tests and provide appropriate treatment. This may involve increasing iron intake or supplementing with vitamin B12.

Hypomagnesemia

If you experience symptoms of hypomagnesemia, seek medical attention immediately. The doctor may order blood tests and provide appropriate treatment. This might include magnesium supplementation.

Nephritis

If you experience symptoms of nephritis, consult a doctor immediately. They may order blood tests and provide necessary treatment.

Comparison Across Studies

Commonalities

Numerous studies have consistently indicated that lansoprazole can cause various side effects. Long-term use of lansoprazole can potentially exacerbate these side effects.

Differences

The specific types and severity of side effects associated with lansoprazole can vary across studies. These variations could be attributed to factors such as the patient population studied, the dosage of lansoprazole administered, and other contributing factors.

Practical Considerations

While lansoprazole effectively reduces stomach acid, leading to relief from symptoms like heartburn and indigestion, it is crucial to remember the potential side effects. It is highly recommended to discuss these risks and benefits with your doctor before starting lansoprazole. If you are on long-term lansoprazole treatment, regular health checkups are important.

Limitations of Current Research

Research on lansoprazole side effects is still limited. More comprehensive studies, including large-scale clinical trials and animal experiments, are needed to understand long-term effects more thoroughly.

Future Research Directions

To gain a more complete understanding of lansoprazole side effects, further research is necessary. This includes conducting extensive clinical trials and animal experiments. Additionally, developing medications that can mitigate lansoprazole's side effects is a desirable goal.

Conclusion

Lansoprazole is a highly effective medication for reducing stomach acid. However, several reported side effects should be considered. Prior to starting lansoprazole, consult your doctor to discuss the potential risks and benefits. Regular health checkups are crucial for those on long-term lansoprazole treatment.

Literature analysis of 26 papers
Positive Content
16
Neutral Content
1
Negative Content
9
Article Type
2
0
0
8
25
1.

Lansoprazole-induced hypomagnesaemia.

Author: KrupaLukasz Zbigniew, FellowsIan Wilfred

Hypomagnesaemia

This case report highlights the importance of considering hypomagnesaemia as a possible side effect of long-term proton pump inhibitor (PPI) therapy. A 73-year-old woman experienced supraventricular tachycardia due to hypomagnesaemia while using lansoprazole. Her arrhythmia resolved after intravenous magnesium replenishment and stopping her PPI. This case underscores the importance of checking serum magnesium concentrations in patients on PPIs, especially those who are unwell or present with arrhythmia.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

2.

Perils and pitfalls of long-term effects of proton pump inhibitors.

Author: WilhelmSheila M, RjaterRyan G, Kale-PradhanPramodini B

Clostridium difficile
Fractures
Iron deficiency
Magnesium absorption
Nephritis
Pneumonia risk
Rhabdomyolysis
Thrombocytopenia
Vitamin B12 deficiency

Proton pump inhibitors (PPIs) are associated with serious adverse effects such as pneumonia, Clostridium difficile infection, and bone fractures.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Proton Pump Inhibitors: Risk for Myopathy?

Author: ColmenaresEvan W, PappasAshley L

Myopathy symptoms

This review of published case reports and an adverse event reporting database suggests that proton pump inhibitor (PPI) use may be associated with myopathy-like symptoms. Although myopathy is a rare side effect, it is a serious one that should be considered when starting a patient on acid suppression therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

A Case of Lansoprazole-Induced Bullous Pemphigoid After Zantac Recall.

Author: TranMinh, ArmentaAndrew M, WilkersonMichael G, AfrouzianMarjan, KhanKashif

Gastroesophageal reflux disease treatment
PPI-induced bullous pemphigoid

This case report describes a patient who developed bullous pemphigoid after initiating lansoprazole for esophagitis.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

6.

Spectroscopic study of in situ-formed metallocomplexes of proton pump inhibitors in water.

Author: AbramenkoNikita, KejíkZdeněk, KaplánekRobert, TatarAmeneh, BrogyányiTereza, PajkováMartina, SýkoraDavid, VeseláKateřina, AntonyováVeronika, DytrychPetr, Ikeda-SaitoMasao, MartásekPavel, JakubekMilan

Amnesia
Neurodegenerative risk
Oncological risk

Proton pump inhibitors (PPIs), such as omeprazole, pantoprazole, and lansoprazole, are widely used for acid reflux and other conditions. This study investigated the potential interaction between these drugs and iron ions in water systems. The results suggest that PPIs may form complexes with iron ions, raising concerns about potential side effects related to iron metabolism.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

[Influence of omeprasole and lansoprasole on Na+, K+ -ATPase and Mg2+ -ATPase activity of the plasmatic membrane of myometrium smooth muscle cells].

Author: VeklichT O, ShkrabakO A, MedvedievV V, Kurs'kyĭM D, KosterinS O

Treats acid-dependent diseases
Side effects

Omeprazole and lansoprazole inhibited Na+, K+ -ATPase activity in the myometrium.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Ukrainian

8.

Colonic toxicity of administered drugs and chemicals.

Author: CappellMitchell S

Colonic hypomotility
Colonic ischemia
Colonic pseudo-obstruction
Hemorrhagic colitis
Inflammatory colitis
Lymphocytic colitis
Neutropenic colitis
Pseudomembranous colitis
Toxic colitis
Yersinia enterocolitis

Medication-induced colonotoxicity, though uncommon, can be serious and requires prompt medication cessation. This review categorizes medications associated with colonotoxicity into various categories, including those associated with ischemia, pseudo-obstruction, colitis, and lymphocytic colitis.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Spontaneous reporting of adverse reactions related to proton pump inhibitors.

Author: DipasqualeValeria, CicalaGiuseppe, LaganàFrancesca, CutroneoPaola, TrimarchiGiuseppe, SpinaEdoardo, RomanoClaudio

Adverse drug reactions

Most PPI-related ADRs are non-serious. Omeprazole and combination therapy seem to be associated with ADR seriousness.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

Proton Pump Inhibitors Increase the Susceptibility of Mice to Oral Infection with Enteropathogenic Bacteria.

Author: YasutomiEiichiro, HoshiNamiko, AdachiSoichiro, OtsukaTakafumi, KongLingling, KuYuna, YamairiHaruka, InoueJun, IshidaTsukasa, WatanabeDaisuke, OoiMakoto, YoshidaMasaru, TsukimiTomoya, FukudaShinji, AzumaTakeshi

Increased susceptibility to enteropathogens

This study investigated the effects of Lansoprazole (Laz) on susceptibility to enteropathogens.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Transmucosal gastric leak induced by proton pump inhibitors.

Author: MurrayLisa J, GabelloMelissa, RudolphDavid S, FarrellChristopher P, MorganMelissa, MartinAaron P, UnderwoodJames C, ValenzanoM Carmen, MullinJames M

No clinical side effects
Safe PPI profile
Increased permeability
Transmucosal gastric leak

Proton pump inhibitors (PPIs), despite their safety profile, induce a transmucosal gastric leak in rats. The study found that PPIs increased transmucosal permeability in a dose-dependent manner, suggesting potential biomedical implications for their widespread use.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

An overview of proton pump inhibitors.

Author: DerGabriella

Treat H. pylori infection
Treat acid-related disorders
Treat upper GI bleeding

Proton pump inhibitors (PPIs) are the standard treatment for acid-related disorders such as gastroesophageal reflux disease and peptic ulcer disease. Five PPIs are currently available in the US: omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole. This review discusses the history, pharmacology, therapeutic indications, clinical efficacy, short- and long-term side effects, and cost of PPIs.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

14.

Recognizing Severe Adverse Drug Reactions: Two Case Reports After Switching Therapies to the Same Generic Company.

Author: GallelliLuca, GallelliGiuseppe, CodamoGiuseppe, ArgentieriAngela, MichniewiczAndzelika, SiniscalchiAntonio, StefanelliRoberta, CioneErika, CaroleoMaria C, LongoPaola, De SarroGiovambattista

Adverse drug reaction

This report describes the development of Adverse Drug Reactions (ADRs) in two patients after the switch from brand to generic formulations. We have tested cytochrome P450 enzymes expression as well as drug serum levels. Checking deeply into both patient's medical history, they harbored poly-sensitivity or allergy to pollen and graminacea. We strongly suggest to both pharmacists and physicians to be careful in giving the advice to change the drug, thinking to reduce health sanitary costs without considering the personal clinical history of each one.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

16.

Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3.

Author: IkemuraKenji, HamadaYugo, KayaChinatsu, EnokiyaTomoyuki, MurakiYuichi, NakaharaHiroki, FujimotoHajime, KobayashiTetsu, IwamotoTakuya, OkudaMasahiro

Cancer treatment
Hematologic toxicity

Pemetrexed, a multitargeted antifolate, is transported via human organic anion transporter 3 (hOAT3). Lansoprazole, a proton pump inhibitor (PPI), was found to inhibit hOAT3-mediated uptake of pemetrexed. This inhibition can lead to increased hematologic toxicity in patients receiving pemetrexed chemotherapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

[Lanzoptol efficiency for heartburn alleviation in patients with NERD].

Author: OsipenkoM F, BikbulatovaE A, ShakaliteIu D

Effective heartburn treatment
Good portability

Lanzoptol (lansoprazol) is an effective and well-tolerated proton pump inhibitor for the treatment of non-erosive reflux disease (NERD). 87% of patients experienced complete relief from heartburn after 4 weeks of treatment, and no side effects were reported.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Russian

18.

High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors.

Author: SpugniniEnrico P, BuglioniSabrina, CarocciFrancesca, FrancescoMenicagli, VincenziBruno, FanciulliMaurizio, FaisStefano

Cancer treatment
Tumor responsiveness

The treatment of human cancer has been hampered by resistance to chemotherapeutic drugs. This study investigated the efficacy of combining metronomic chemotherapy with high dose proton-pump inhibitors (PPIs) in treating pets with spontaneously occurring cancer.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Practical considerations in the management of proton-pump inhibitors.

Author: Aguilera-CastroLara, Martín-de-Argila-dePradosCarlos, Albillos-MartínezAgustín

H. pylori eradication
esophagitis healing
Side effects

This article discusses the overuse of proton-pump inhibitors (PPIs) in Spain, highlighting the importance of appropriate indications and doses. It compares different types of PPIs and generic versions of these drugs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

21.

[Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].

Author: MaevI V, BalashovaN N, BusarovaG A

Heal esophageal lesions
Relief GERD symptoms

Proton pump inhibitors (PPIs) are the first-line therapy for gastroesophageal reflux disease (GERD). They are effective in relieving symptoms and healing erosive-ulcerous lesions of the esophageal mucosa. However, the widespread use of PPIs requires further investigation of their long-term side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : Russian

22.

Dermatologic adverse reactions to proton-pump inhibitors: A synthetized review.

Author: SalloumAntoine, NasrDayana, MaaloufDiane

PPI hypersensitivity
PPI skin reactions

Proton-pump inhibitors (PPIs), commonly prescribed medications, can induce a range of cutaneous adverse reactions, including immediate and delayed-type hypersensitivity reactions. Some reactions can be life-threatening. PPIs should be considered as a possible culprit for new cutaneous drug reactions, and skin tests can help confirm hypersensitivity reactions.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

23.

The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study.

Author: ErgülBilal, DoğanZeynal, SarikayaMurat, FilikLevent

Acceptable eradication rate
Side effects

A 14-day bismuth-lansoprazole-amoxicillin-clarithromycin (BLAC) regimen achieved an acceptable Helicobacter pylori eradication rate of 90.7% with relatively mild side effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

24.

The effect of rebamipide on non-steroidal anti-inflammatory drug-induced gastro-enteropathy: a multi-center, randomized pilot study.

Author: OhDong Jun, YoonHyuk, KimHyun Soo, ChoiYoon Jin, ShinCheol Min, ParkYoung Soo, KimNayoung, LeeDong Ho, HaYou-Jung, KangEun Ha, LeeYun Jong, KimKi-Jeoung, LiuFei

NSAID gastroenteropathy treatment
NSAID gastroenteropathy

This study examines the efficacy, safety, and gastrointestinal effects of rebamipide and proton pump inhibitors (PPIs) in patients requiring long-term non-steroidal anti-inflammatory drug (NSAID) use. NSAIDs are commonly prescribed for conditions like arthritis and heart disease but can lead to gastrointestinal problems such as bleeding and ulcers. The study aims to evaluate the benefits and risks associated with rebamipide and PPIs in mitigating these gastrointestinal complications.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

25.

[Low-dose aspirin (LDA)/nonsteroidal anti-inflammatory drugs(NSAIDs)-induced gastrointestinal injury in Japan].

Author: SuganoKentaro

Prevent GI ulcer
GI bleeding

This article discusses the frequent prescription of low-dose aspirin (LDA) and nonsteroidal anti-inflammatory drugs (NSAIDs) in Japan. It highlights the gastrointestinal injury associated with their use and the importance of preventing LDA/NSAIDs-induced gastrointestinal ulcer.

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : Japanese

26.

Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.

Author: ChenLuyi, HeJiamin, WangLan, GeQiwei, ChuHua, ChenYujia, ChenXiaoli, LongYanqin, DengYanyong, HeHuiqin, LiAiqing, ChenShujie

H. pylori eradication
Gastrointestinal symptoms

A 14-day bismuth-furazolidone quadruple regimen is effective and safe for the initial eradication of Helicobacter pylori (H. pylori). In a study of 175 patients, the total eradication rate was 86.9% by intention-to-treat and 95.6% by per-protocol analysis. The efficacies of five different proton pump inhibitors (PPIs) showed no significant difference. Gastrointestinal symptoms and stool type improved significantly, while the total side effect rate and poor compliance rate were 15.7% and 5.0%, respectively.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.